New model more accurately classifies breast cancer risk
the ONA take:
Every year in America, more than a million women have breast biopsies that turn out to have benign findings. A new model, tested by a group of researchers led by Amy Degnim, M.D., a surgeon at Mayo Clinic, uses histologic features of biopsied breast tissue from benign findings along with demographic data to more accurately determine future breast cancer risk.
To test their new model, the investigators examined a cohort of approximately ten thousand women who received benign breast biopsy results from the Mayo Clinic but later developed breast cancer. The resulting age-specific incidence data was combined with a relative risk model created from both matched controls and 377 patients that later developed breast cancer.
Risk predictions from the new model were compared to the current standard, the Breast Cancer Risk Assessment Tool (BCRAT). The concordance statistic (both in the model development series and the validation series) was found to be higher in the new model than from the BCRAT.
A more accurate model for early breast cancer prediction could prove extremely useful, given that women with benign breast disease stand a higher risk of eventually developing breast cancer. This research was published in the Journal of Clinical Oncology.
Histologic features of biopsied breast tissue from benign findings along with demographic data to more accurately determine risk.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|